Repros Therapeutics Inc. (NASDAQ:RPRX) reported a loss of 20 cents per share in the first quarter of 2016, significantly narrower than the year-ago loss of 35 cents mainly due to lower research & development (R&D) expenses. First-quarter revenues (interest income) increased to $17,000 from $1,000 in the year-ago period.
R&D costs decreased 48.6% year over year to $3.8 million reflecting lower development expenses related to the enclomiphene product candidate, R&D payroll and benefits expenses and legal expenses, partially offset by higher development expenses related to Proellex. General and administrative expenses also decreased 9% year over year to $1.1 million.
Proellex is being evaluated for uterine fibroids and endometriosis.
Enclomiphene, which was issued a complete response letter (CRL) by the FDA in late 2015, is being developed for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Repros is currently conducting a phase II double-blind, placebo controlled, proof of concept study (ZA-205), in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. Six month data is expected in the third quarter of 2016.
Considering that Repros has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.
Repros is a Zacks Rank #2 (Buy) stock. Some better-ranked stocks in the health care sector are Apricus Biosciences, Inc. (NASDAQ:APRI) , ArQule Inc. (NASDAQ:ARQL) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) . All three carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
REPROS THERAPEU (RPRX): Free Stock Analysis Report
BIOSPECIFICS TE (BSTC): Free Stock Analysis Report
APPRICUS BIOSCI (APRI): Free Stock Analysis Report
ARQULE INC (ARQL): Free Stock Analysis Report
Original post
Zacks Investment Research
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline In Focus
Published 05/10/2016, 09:01 PM
Updated 07/09/2023, 06:31 AM
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline In Focus
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Latest comments
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.